nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—PRKD1—urethra—penile cancer	0.0179	0.0211	CbGeAlD
Crizotinib—PRKD3—urethra—penile cancer	0.0173	0.0203	CbGeAlD
Crizotinib—DSTYK—urethra—penile cancer	0.0168	0.0198	CbGeAlD
Crizotinib—MAPK7—urethra—penile cancer	0.0159	0.0187	CbGeAlD
Crizotinib—MET—skin of body—penile cancer	0.0156	0.0183	CbGeAlD
Crizotinib—TAOK2—urethra—penile cancer	0.0143	0.0168	CbGeAlD
Crizotinib—IKBKE—lymph node—penile cancer	0.0131	0.0154	CbGeAlD
Crizotinib—DCLK1—urethra—penile cancer	0.0131	0.0154	CbGeAlD
Crizotinib—TYRO3—skin of body—penile cancer	0.0127	0.015	CbGeAlD
Crizotinib—IGF1R—skin of body—penile cancer	0.0122	0.0144	CbGeAlD
Crizotinib—FER—urethra—penile cancer	0.0122	0.0143	CbGeAlD
Crizotinib—TNK1—urethra—penile cancer	0.0121	0.0142	CbGeAlD
Crizotinib—MAP4K2—urethra—penile cancer	0.0116	0.0136	CbGeAlD
Crizotinib—TIE1—urethra—penile cancer	0.0114	0.0134	CbGeAlD
Crizotinib—TESK1—urethra—penile cancer	0.011	0.013	CbGeAlD
Crizotinib—MERTK—urethra—penile cancer	0.0107	0.0126	CbGeAlD
Crizotinib—STK35—skin of body—penile cancer	0.0106	0.0125	CbGeAlD
Crizotinib—MAP3K12—urethra—penile cancer	0.0104	0.0122	CbGeAlD
Crizotinib—ACVR1—urethra—penile cancer	0.0104	0.0122	CbGeAlD
Crizotinib—RIPK2—skin of body—penile cancer	0.00979	0.0115	CbGeAlD
Crizotinib—NEK9—lymph node—penile cancer	0.00939	0.011	CbGeAlD
Crizotinib—RIPK2—urethra—penile cancer	0.00938	0.011	CbGeAlD
Crizotinib—PTK2—skin of body—penile cancer	0.00909	0.0107	CbGeAlD
Crizotinib—EPHA4—urethra—penile cancer	0.00906	0.0106	CbGeAlD
Crizotinib—TYK2—skin of body—penile cancer	0.00903	0.0106	CbGeAlD
Crizotinib—EPHA7—Axon guidance—SCN10A—penile cancer	0.00883	0.0594	CbGpPWpGaD
Crizotinib—TBK1—urethra—penile cancer	0.00871	0.0102	CbGeAlD
Crizotinib—PTK2—urethra—penile cancer	0.00871	0.0102	CbGeAlD
Crizotinib—AXL—skin of body—penile cancer	0.00865	0.0102	CbGeAlD
Crizotinib—TYK2—urethra—penile cancer	0.00865	0.0102	CbGeAlD
Crizotinib—PRKD1—lymph node—penile cancer	0.00856	0.0101	CbGeAlD
Crizotinib—LIMK1—lymph node—penile cancer	0.00845	0.00992	CbGeAlD
Crizotinib—RPS6KB1—urethra—penile cancer	0.00838	0.00984	CbGeAlD
Crizotinib—LCK—urethra—penile cancer	0.00832	0.00978	CbGeAlD
Crizotinib—FGR—urethra—penile cancer	0.00832	0.00978	CbGeAlD
Crizotinib—AXL—urethra—penile cancer	0.00829	0.00974	CbGeAlD
Crizotinib—PRKD3—lymph node—penile cancer	0.00823	0.00967	CbGeAlD
Crizotinib—JAK2—skin of body—penile cancer	0.00821	0.00965	CbGeAlD
Crizotinib—DSTYK—lymph node—penile cancer	0.00803	0.00943	CbGeAlD
Crizotinib—SLK—urethra—penile cancer	0.00798	0.00937	CbGeAlD
Crizotinib—BLK—lymph node—penile cancer	0.00794	0.00933	CbGeAlD
Crizotinib—EPHB4—urethra—penile cancer	0.00792	0.00931	CbGeAlD
Crizotinib—MAP3K3—skin of body—penile cancer	0.00792	0.0093	CbGeAlD
Crizotinib—JAK2—urethra—penile cancer	0.00787	0.00924	CbGeAlD
Crizotinib—CASK—lymph node—penile cancer	0.00785	0.00922	CbGeAlD
Crizotinib—LTK—lymph node—penile cancer	0.00785	0.00922	CbGeAlD
Crizotinib—EPHA2—urethra—penile cancer	0.00777	0.00913	CbGeAlD
Crizotinib—MAPK7—lymph node—penile cancer	0.0076	0.00893	CbGeAlD
Crizotinib—TXK—lymph node—penile cancer	0.0076	0.00893	CbGeAlD
Crizotinib—MAP4K5—urethra—penile cancer	0.00758	0.00891	CbGeAlD
Crizotinib—MAP3K3—urethra—penile cancer	0.00758	0.00891	CbGeAlD
Crizotinib—TEK—urethra—penile cancer	0.00758	0.00891	CbGeAlD
Crizotinib—EPHB6—skin of body—penile cancer	0.00756	0.00888	CbGeAlD
Crizotinib—FES—lymph node—penile cancer	0.00753	0.00884	CbGeAlD
Crizotinib—EPHB6—urethra—penile cancer	0.00725	0.00851	CbGeAlD
Crizotinib—MET—lymph node—penile cancer	0.00712	0.00836	CbGeAlD
Crizotinib—SRC—skin of body—penile cancer	0.00703	0.00826	CbGeAlD
Crizotinib—YES1—urethra—penile cancer	0.007	0.00823	CbGeAlD
Crizotinib—TAOK3—urethra—penile cancer	0.00691	0.00812	CbGeAlD
Crizotinib—CDK7—lymph node—penile cancer	0.00688	0.00809	CbGeAlD
Crizotinib—TAOK2—lymph node—penile cancer	0.00683	0.00802	CbGeAlD
Crizotinib—ACVR1B—lymph node—penile cancer	0.00658	0.00773	CbGeAlD
Crizotinib—EPHA3—lymph node—penile cancer	0.00658	0.00773	CbGeAlD
Crizotinib—CSF1R—skin of body—penile cancer	0.00631	0.00742	CbGeAlD
Crizotinib—EPHA7—Developmental Biology—SCN10A—penile cancer	0.0063	0.0424	CbGpPWpGaD
Crizotinib—JAK3—lymph node—penile cancer	0.00628	0.00737	CbGeAlD
Crizotinib—DCLK1—lymph node—penile cancer	0.00624	0.00733	CbGeAlD
Crizotinib—PLK4—lymph node—penile cancer	0.0062	0.00728	CbGeAlD
Crizotinib—STK4—lymph node—penile cancer	0.00616	0.00724	CbGeAlD
Crizotinib—CSF1R—urethra—penile cancer	0.00605	0.0071	CbGeAlD
Crizotinib—ALK—lymph node—penile cancer	0.00582	0.00684	CbGeAlD
Crizotinib—FER—lymph node—penile cancer	0.00582	0.00684	CbGeAlD
Crizotinib—MET—Axon guidance—SCN10A—penile cancer	0.0058	0.039	CbGpPWpGaD
Crizotinib—TNK1—lymph node—penile cancer	0.00576	0.00677	CbGeAlD
Crizotinib—MAP4K1—lymph node—penile cancer	0.0057	0.0067	CbGeAlD
Crizotinib—BMPR1B—lymph node—penile cancer	0.0057	0.0067	CbGeAlD
Crizotinib—IGF1R—lymph node—penile cancer	0.00559	0.00657	CbGeAlD
Crizotinib—TNK2—lymph node—penile cancer	0.00559	0.00657	CbGeAlD
Crizotinib—MAP4K2—lymph node—penile cancer	0.00552	0.00648	CbGeAlD
Crizotinib—STK3—lymph node—penile cancer	0.00544	0.00639	CbGeAlD
Crizotinib—TIE1—lymph node—penile cancer	0.00544	0.00639	CbGeAlD
Crizotinib—AURKA—lymph node—penile cancer	0.0053	0.00623	CbGeAlD
Crizotinib—TESK1—lymph node—penile cancer	0.00526	0.00618	CbGeAlD
Crizotinib—MERTK—lymph node—penile cancer	0.00512	0.00601	CbGeAlD
Crizotinib—FES—Axon guidance—SCN10A—penile cancer	0.00507	0.0341	CbGpPWpGaD
Crizotinib—LIMK2—lymph node—penile cancer	0.005	0.00588	CbGeAlD
Crizotinib—ABL1—skin of body—penile cancer	0.00499	0.00586	CbGeAlD
Crizotinib—NUAK2—lymph node—penile cancer	0.00499	0.00586	CbGeAlD
Crizotinib—ACVR1—lymph node—penile cancer	0.00495	0.00582	CbGeAlD
Crizotinib—MAP3K12—lymph node—penile cancer	0.00495	0.00582	CbGeAlD
Crizotinib—FLT3—lymph node—penile cancer	0.00495	0.00582	CbGeAlD
Crizotinib—STK35—lymph node—penile cancer	0.00485	0.0057	CbGeAlD
Crizotinib—EPHA5—Axon guidance—SCN10A—penile cancer	0.00481	0.0323	CbGpPWpGaD
Crizotinib—ABL2—Axon guidance—SCN10A—penile cancer	0.00481	0.0323	CbGpPWpGaD
Crizotinib—EPHA3—Axon guidance—SCN10A—penile cancer	0.00481	0.0323	CbGpPWpGaD
Crizotinib—ABL1—urethra—penile cancer	0.00478	0.00562	CbGeAlD
Crizotinib—ACVR1B—Developmental Biology—SCN10A—penile cancer	0.00477	0.0321	CbGpPWpGaD
Crizotinib—ABL2—lymph node—penile cancer	0.00473	0.00555	CbGeAlD
Crizotinib—BMP2K—lymph node—penile cancer	0.00467	0.00548	CbGeAlD
Crizotinib—EPHA8—Axon guidance—SCN10A—penile cancer	0.00464	0.0312	CbGpPWpGaD
Crizotinib—LIMK2—Axon guidance—SCN10A—penile cancer	0.00458	0.0308	CbGpPWpGaD
Crizotinib—EPHA4—Axon guidance—SCN10A—penile cancer	0.00458	0.0308	CbGpPWpGaD
Crizotinib—EPHB4—Axon guidance—SCN10A—penile cancer	0.00458	0.0308	CbGpPWpGaD
Crizotinib—PTK2B—lymph node—penile cancer	0.00451	0.0053	CbGeAlD
Crizotinib—LIMK1—Axon guidance—SCN10A—penile cancer	0.00449	0.0302	CbGpPWpGaD
Crizotinib—RIPK2—lymph node—penile cancer	0.00447	0.00525	CbGeAlD
Crizotinib—EPHA4—lymph node—penile cancer	0.00432	0.00508	CbGeAlD
Crizotinib—EPHB6—Axon guidance—SCN10A—penile cancer	0.00431	0.029	CbGpPWpGaD
Crizotinib—MAP3K2—lymph node—penile cancer	0.00424	0.00498	CbGeAlD
Crizotinib—PTK2—lymph node—penile cancer	0.00415	0.00488	CbGeAlD
Crizotinib—TBK1—lymph node—penile cancer	0.00415	0.00488	CbGeAlD
Crizotinib—MET—Developmental Biology—SCN10A—penile cancer	0.00414	0.0278	CbGpPWpGaD
Crizotinib—TYK2—lymph node—penile cancer	0.00412	0.00484	CbGeAlD
Crizotinib—IRAK1—lymph node—penile cancer	0.00407	0.00478	CbGeAlD
Crizotinib—EPHA6—Axon guidance—SCN10A—penile cancer	0.00405	0.0273	CbGpPWpGaD
Crizotinib—RPS6KB1—lymph node—penile cancer	0.00399	0.00469	CbGeAlD
Crizotinib—LCK—lymph node—penile cancer	0.00397	0.00466	CbGeAlD
Crizotinib—FGR—lymph node—penile cancer	0.00397	0.00466	CbGeAlD
Crizotinib—AXL—lymph node—penile cancer	0.00395	0.00464	CbGeAlD
Crizotinib—SLK—lymph node—penile cancer	0.00381	0.00447	CbGeAlD
Crizotinib—EPHB4—lymph node—penile cancer	0.00378	0.00444	CbGeAlD
Crizotinib—JAK2—lymph node—penile cancer	0.00375	0.00441	CbGeAlD
Crizotinib—EPHA2—Axon guidance—SCN10A—penile cancer	0.00374	0.0251	CbGpPWpGaD
Crizotinib—EPHA2—lymph node—penile cancer	0.00371	0.00435	CbGeAlD
Crizotinib—FES—Developmental Biology—SCN10A—penile cancer	0.00362	0.0243	CbGpPWpGaD
Crizotinib—TEK—lymph node—penile cancer	0.00362	0.00425	CbGeAlD
Crizotinib—MAP4K5—lymph node—penile cancer	0.00362	0.00425	CbGeAlD
Crizotinib—MAP3K3—lymph node—penile cancer	0.00362	0.00425	CbGeAlD
Crizotinib—EPHB6—lymph node—penile cancer	0.00346	0.00406	CbGeAlD
Crizotinib—EPHA5—Developmental Biology—SCN10A—penile cancer	0.00343	0.0231	CbGpPWpGaD
Crizotinib—ABL2—Developmental Biology—SCN10A—penile cancer	0.00343	0.0231	CbGpPWpGaD
Crizotinib—EPHA3—Developmental Biology—SCN10A—penile cancer	0.00343	0.0231	CbGpPWpGaD
Crizotinib—YES1—lymph node—penile cancer	0.00334	0.00392	CbGeAlD
Crizotinib—STK10—lymph node—penile cancer	0.00331	0.00389	CbGeAlD
Crizotinib—EPHA8—Developmental Biology—SCN10A—penile cancer	0.00331	0.0223	CbGpPWpGaD
Crizotinib—TAOK3—lymph node—penile cancer	0.0033	0.00387	CbGeAlD
Crizotinib—SRC—L1CAM interactions—SCN10A—penile cancer	0.00327	0.022	CbGpPWpGaD
Crizotinib—EPHB4—Developmental Biology—SCN10A—penile cancer	0.00327	0.022	CbGpPWpGaD
Crizotinib—EPHA4—Developmental Biology—SCN10A—penile cancer	0.00327	0.022	CbGpPWpGaD
Crizotinib—LIMK2—Developmental Biology—SCN10A—penile cancer	0.00327	0.022	CbGpPWpGaD
Crizotinib—SRC—lymph node—penile cancer	0.00321	0.00377	CbGeAlD
Crizotinib—LIMK1—Developmental Biology—SCN10A—penile cancer	0.0032	0.0215	CbGpPWpGaD
Crizotinib—EPHB6—Developmental Biology—SCN10A—penile cancer	0.00308	0.0207	CbGpPWpGaD
Crizotinib—EPHA6—Developmental Biology—SCN10A—penile cancer	0.00289	0.0195	CbGpPWpGaD
Crizotinib—CSF1R—lymph node—penile cancer	0.00288	0.00339	CbGeAlD
Crizotinib—EPHA2—Developmental Biology—SCN10A—penile cancer	0.00267	0.0179	CbGpPWpGaD
Crizotinib—PTK2—Axon guidance—SCN10A—penile cancer	0.00232	0.0156	CbGpPWpGaD
Crizotinib—YES1—Axon guidance—SCN10A—penile cancer	0.00229	0.0154	CbGpPWpGaD
Crizotinib—ABL1—lymph node—penile cancer	0.00228	0.00268	CbGeAlD
Crizotinib—TYK2—Axon guidance—SCN10A—penile cancer	0.0021	0.0142	CbGpPWpGaD
Crizotinib—LYN—Axon guidance—SCN10A—penile cancer	0.0017	0.0115	CbGpPWpGaD
Crizotinib—ABL1—Axon guidance—SCN10A—penile cancer	0.0017	0.0114	CbGpPWpGaD
Crizotinib—PTK2—Developmental Biology—SCN10A—penile cancer	0.00165	0.0111	CbGpPWpGaD
Crizotinib—YES1—Developmental Biology—SCN10A—penile cancer	0.00163	0.011	CbGpPWpGaD
Crizotinib—JAK2—Axon guidance—SCN10A—penile cancer	0.0016	0.0107	CbGpPWpGaD
Crizotinib—TYK2—Developmental Biology—SCN10A—penile cancer	0.0015	0.0101	CbGpPWpGaD
Crizotinib—ABCB1—urethra—penile cancer	0.00149	0.00175	CbGeAlD
Crizotinib—SRC—Axon guidance—SCN10A—penile cancer	0.00124	0.00832	CbGpPWpGaD
Crizotinib—LYN—Developmental Biology—SCN10A—penile cancer	0.00122	0.00819	CbGpPWpGaD
Crizotinib—ABL1—Developmental Biology—SCN10A—penile cancer	0.00121	0.00815	CbGpPWpGaD
Crizotinib—JAK2—Developmental Biology—SCN10A—penile cancer	0.00114	0.00766	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—SCN10A—penile cancer	0.000883	0.00594	CbGpPWpGaD
Crizotinib—ABCB1—lymph node—penile cancer	0.000709	0.000833	CbGeAlD
